MNKD · MannKind Corporation — research history
Complete research history. Every dossier, draft, kill, publish, and lesson the system has produced on MNKD. Public so users can audit, AI can re-reference. Live price refreshes every 60s.
About MNKD · MannKind Corporation
MannKind Corporation, a biopharmaceutical company, focuses on the provision of various solutions for transforming chronic disease care. It develops and commercializes treatments that address serious unmet medical needs, including diabetes, pulmonary hypertension, and fluid overload in heart failure and chronic kidney disease. It offers Afrezza inhalation powder, an inhaled insulin used to improve glycemic control in adults with diabetes; and the V-Go wearable insulin delivery device, which provides continuous subcutaneous infusion of insulin in adults. Its products also include Tyvaso DPI for the treatment of pulmonary arterial hypertension and pulmonary hypertension associated with interstitial lung disease; FUROSCIX, a furosemide injection to treat fluid buildup in patients with chronic heart failure or chronic kidney disease. The company's pipeline of treatments for orphan lung diseases include MNKD-201, a dry-powder formulation of nintedanib for the treatment of idiopathic pulmonary fibrosis and MNKD-701. It has collaboration and license agreement with United Therapeutics Corporation for development, regulatory, and commercial activities of Tyvaso DPI; and collaboration agreement with Thirona to evaluate the therapeutic for the treatment of pulmonary fibrosis. MannKind Corporation was incorporated in 1991 and is headquartered in Danbury, Connecticut.
Live Quote
HOLD (score -2) · 12-1 mom -17.0% · RSI 63.2 · above_50_only · -36.7% from high
Targets blend Wall Street consensus (8 analysts: low $4.75 / mean $7.59 / high $11.00) with chart-derived floors and ceilings.
1-Year Chart · RSI · MACD
Research Timeline
Newest first. Each entry shows what stage produced it, the verdict/decision, and the reasoning.
Stage produced output that could not be parsed as a valid JSON object. ~6h cooldown before retry.
{"symbol":"MNKD","company":"MannKind Corporation","investigation_summary":"MNKD has collapsed ~50% from its 52-week high following a Q1 2026 earnings miss (-400% EPS surprise) after the scPharmaceuticals acquisition drove elevated costs. The stock is now deeply out of favor despite two imminent FDA decisions (Afrezza pediatric PDUFA May 29; Furoscix ReadyFlow July 26), an expanded United Therapeut